Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): Study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. [Trials. 52, (2017), (18)] DOI: 10.1186/s13063-017-1777-y

Celine Busard; Stef Menting; Sun Jine van Bezooijen; Juul van den Reek; Barbara Hutten; Errol Prens; Elke de Jong; Martijn van Doorn; Phyllis Spuls

ArticleOPEN ACCESS

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): Study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. [Trials. 52, (2017), (18)] DOI: 10.1186/s13063-017-1777-y

Trials

DOI: 10.1186/s13063-017-1848-0

3Citations

15Readers

Abstract

The author initials were not complete in the original publication [1]. The correct initials should be: "CI Busard, SP Menting, JS van Bezooijen, JM van den Reek, BA Hutten, EP Prens, EM de Jong, MB van Doorn, PI Spuls".

Cite

CITATION STYLE

APA

Busard, C., Menting, S., van Bezooijen, S. J., van den Reek, J., Hutten, B., Prens, E., … Spuls, P. (2017, March 7). Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): Study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. [Trials. 52, (2017), (18)] DOI: 10.1186/s13063-017-1777-y. Trials. BioMed Central Ltd. https://doi.org/10.1186/s13063-017-1848-0

Erratum to: Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): Study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. [Trials. 52, (2017), (18)] DOI: 10.1186/s13063-017-1777-y

Abstract

Cite

Register to see more suggestions